JP2012107063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012107063A5 JP2012107063A5 JP2012044260A JP2012044260A JP2012107063A5 JP 2012107063 A5 JP2012107063 A5 JP 2012107063A5 JP 2012044260 A JP2012044260 A JP 2012044260A JP 2012044260 A JP2012044260 A JP 2012044260A JP 2012107063 A5 JP2012107063 A5 JP 2012107063A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- target tumor
- composition according
- target
- inhibitory factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 210000000130 stem cell Anatomy 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 102000015278 OSM-LIF Receptors Human genes 0.000 claims 14
- 108010064527 OSM-LIF Receptors Proteins 0.000 claims 14
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 12
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 12
- 230000011664 signaling Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 4
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 239000011324 bead Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000014500 neuronal tumor Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70085905P | 2005-07-19 | 2005-07-19 | |
| US60/700,859 | 2005-07-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Division JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262190A Division JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012107063A JP2012107063A (ja) | 2012-06-07 |
| JP2012107063A5 true JP2012107063A5 (enExample) | 2013-01-17 |
| JP5891068B2 JP5891068B2 (ja) | 2016-03-22 |
Family
ID=37420973
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Active JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2012044260A Active JP5891068B2 (ja) | 2005-07-19 | 2012-02-29 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Active JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9220756B2 (enExample) |
| EP (2) | EP3117833B1 (enExample) |
| JP (3) | JP5189977B2 (enExample) |
| KR (2) | KR101311061B1 (enExample) |
| AU (1) | AU2006271308B2 (enExample) |
| CA (2) | CA2615491C (enExample) |
| DK (2) | DK1904093T3 (enExample) |
| ES (2) | ES2686093T3 (enExample) |
| HR (1) | HRP20181379T1 (enExample) |
| HU (2) | HUE042197T2 (enExample) |
| NZ (2) | NZ598031A (enExample) |
| PL (2) | PL1904093T3 (enExample) |
| WO (1) | WO2007010394A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2615491C (en) * | 2005-07-19 | 2016-11-29 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| EP2259792B1 (en) | 2008-02-13 | 2011-10-05 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Bone morphogenetic proteins for use in treating and preventing neuroblastomas |
| CN109311956A (zh) | 2015-08-25 | 2019-02-05 | 伊斯迪德股份公司 | 诱导组织形成的化合物及其应用 |
| SG10201913355RA (en) * | 2015-09-17 | 2020-02-27 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| WO2017046226A2 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof. |
| CA2998455A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| KR20180052682A (ko) * | 2015-09-17 | 2018-05-23 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| EP3875102A1 (en) * | 2015-09-17 | 2021-09-08 | Histide AG | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| EP3936149A4 (en) * | 2018-12-28 | 2023-02-15 | The University of Tokyo | THERAPEUTIC AND PROPHYLACTIC AGENT FOR GLIOM, MARKER OF MALIGNITY OF BRAIN TUMOR, PROGNOSTIC MARKER OF BRAIN TUMOR, METHODS OF DETERMINING BRAIN TUMOR MALIGNITY AND PROGNOSIS AND INHIBITING TUMOR PROLIFERATION |
| WO2026022122A1 (en) * | 2024-07-23 | 2026-01-29 | Eos Research Sa | Checkpoint inhibitors in the treatment of glioblastoma multiforme |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| AU3251693A (en) * | 1991-12-24 | 1993-07-28 | Amrad Operations Pty. Limited | A method for the treatment of tumours and sarcomas |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US7592428B1 (en) * | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| CA2187902A1 (en) * | 1994-04-29 | 1995-11-09 | Peter Ten Dijke | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| HUP9902418A3 (en) | 1996-05-09 | 2001-10-29 | Dimensional Pharm Inc | Microplate thermal shift assay and apparatus for ligand development and multi-variable protein chemistry optimization |
| ATE275416T1 (de) | 1998-11-13 | 2004-09-15 | Curis Inc | Verfahren zur verminderung von krebssymptomen |
| CA2393159C (en) * | 1999-12-06 | 2010-04-20 | Paul Calabresi | Methods of treating tumors |
| CA2401989A1 (en) * | 2000-03-03 | 2001-09-07 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment |
| DE602004030809D1 (de) | 2003-09-12 | 2011-02-10 | Stemcell Technologies Inc | Test für neurale koloniebildung |
| JP2005098727A (ja) | 2003-09-22 | 2005-04-14 | Hosiden Corp | 振動センサ |
| US7816088B2 (en) | 2003-12-05 | 2010-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
| CA2571218C (en) * | 2004-06-17 | 2015-11-03 | William D. Carlson | Tdf-related compounds and analogs thereof |
| CA2615491C (en) * | 2005-07-19 | 2016-11-29 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| WO2015050844A1 (en) * | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
-
2006
- 2006-07-19 CA CA2615491A patent/CA2615491C/en active Active
- 2006-07-19 NZ NZ598031A patent/NZ598031A/xx unknown
- 2006-07-19 WO PCT/IB2006/002296 patent/WO2007010394A2/en not_active Ceased
- 2006-07-19 KR KR1020127028173A patent/KR101311061B1/ko active Active
- 2006-07-19 ES ES06795317.4T patent/ES2686093T3/es active Active
- 2006-07-19 US US11/996,214 patent/US9220756B2/en active Active
- 2006-07-19 CA CA2790675A patent/CA2790675C/en active Active
- 2006-07-19 DK DK06795317.4T patent/DK1904093T3/en active
- 2006-07-19 JP JP2008522091A patent/JP5189977B2/ja active Active
- 2006-07-19 NZ NZ565172A patent/NZ565172A/xx unknown
- 2006-07-19 AU AU2006271308A patent/AU2006271308B2/en active Active
- 2006-07-19 DK DK16171392.0T patent/DK3117833T3/en active
- 2006-07-19 HU HUE16171392A patent/HUE042197T2/hu unknown
- 2006-07-19 PL PL06795317T patent/PL1904093T3/pl unknown
- 2006-07-19 HU HUE06795317A patent/HUE040063T2/hu unknown
- 2006-07-19 ES ES16171392T patent/ES2710601T3/es active Active
- 2006-07-19 KR KR1020087003552A patent/KR101338533B1/ko active Active
- 2006-07-19 EP EP16171392.0A patent/EP3117833B1/en active Active
- 2006-07-19 PL PL16171392T patent/PL3117833T3/pl unknown
- 2006-07-19 EP EP06795317.4A patent/EP1904093B1/en active Active
- 2006-07-19 HR HRP20181379TT patent/HRP20181379T1/hr unknown
-
2012
- 2012-02-29 JP JP2012044260A patent/JP5891068B2/ja active Active
-
2014
- 2014-12-25 JP JP2014262190A patent/JP2015057452A/ja not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,157 patent/US9737589B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012107063A5 (enExample) | ||
| Najafiyan et al. | Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies | |
| Lam et al. | Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries | |
| Lammers | Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations | |
| Nör et al. | The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| JP2014530220A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2016517888A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| BR112016013026A2 (pt) | compostos para receptor-3 de fator de crescimento de fibroblasto (fgfr3) e métodos de tratamento | |
| TWI544920B (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| JP2013542205A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| EA200802350A3 (ru) | Система доставки лекарств | |
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Peng et al. | Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma | |
| JP2016515550A5 (enExample) | ||
| JP2009510165A5 (enExample) | ||
| BR112015011294A8 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas |